BioLineRx Ltd.
BLRX
$3.39
$0.020.56%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -132.58% | 87.26% | 85.05% | 74.03% | 93.09% |
| Total Depreciation and Amortization | -88.83% | -88.95% | -21.71% | 32.08% | 66.07% |
| Total Amortization of Deferred Charges | -94.32% | 5.66% | 14.41% | 14.41% | 2,347.46% |
| Total Other Non-Cash Items | 88.28% | 46.59% | -98.50% | -1,268.44% | -254.88% |
| Change in Net Operating Assets | 119.76% | 105.77% | 111.49% | -18.43% | -378.18% |
| Cash from Operations | 76.01% | 81.60% | 55.46% | 30.13% | -12.73% |
| Capital Expenditure | -47.62% | 52.83% | 108.00% | 107.89% | 81.90% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -47.78% | -128.95% | 239.94% | 215.33% | -60.96% |
| Cash from Investing | -48.23% | -129.09% | 235.40% | 214.47% | -60.75% |
| Total Debt Issued | -- | -- | -100.00% | -100.00% | -- |
| Total Debt Repaid | 67.69% | 66.47% | -328.21% | -333.56% | -439.96% |
| Issuance of Common Stock | -88.27% | -16.09% | 36.99% | 8.58% | 59.92% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -105.63% | -56.99% | -73.06% | -77.17% | 118.15% |
| Foreign Exchange rate Adjustments | 678.38% | 2,395.45% | 1,026.92% | 687.13% | -48.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -314.45% | -216.26% | -183.14% | -406.03% | 199.02% |